AmeriPath

Pathology laboratory services
Invested in
1994
Status

IPO 1997  

Acquired by Quest Diagnostics 2007

Location
Riviera Beach, FL
Sector
Healthcare & Life Sciences
Sector
Growth Products & Services

"Summit helped us successfully execute our acquisition strategy, providing invaluable expertise along with capital."

Jim New
Former CEO
|
AmeriPath
22x

Revenue growth over Summit’s 6-year investment period

35+

Pathology practices acquired

IPO

Completed IPO in 1997

22x

Revenue growth over Summit’s 6-year investment period

35+

Pathology practices acquired

IPO

Completed IPO in 1997

Founded by physicians, AmeriPath specialized in dermatopathalogy, the review and interpretation of human tissue biopsies. While the company had developed a strong and loyal referring physician customer base in the southeastern United States, the founders aspired to expand the business to a national scale through the consolidation of the fragmented industry. The company turned to Summit for financing and strategic guidance.

How Summit Partners Helped

  • Provided growth equity capital, subordinated debt and arranged for a bank line of credit
  • At the founders’ request, recruited a seasoned healthcare executive as CEO
  • Helped build an independent board of directors
  • Led several bank financings to help facilitate a successful acquisition strategy

AmeriPath completed its IPO in 1997, and Summit exited the investment in 2000. The company continued to grow rapidly, expanding across the United States and broadening its services to offer a range of anatomic pathology laboratory testing and information services. In 2007, AmeriPath was acquired by Quest Diagnostics for $2 billion.

The Portfolio Company Executive quoted herein did not receive compensation for any statements regarding Summit Partners. However, since AmeriPath is a former portfolio company of Summit, this individual did receive general compensation in connection with his employment by the company. In addition, this individual is not an investor in a Summit fund but may have conflicts arising from his past role with AmeriPath due to the company’s relationship with Summit.

Related News

No items found.
No items found.
Button Text

Get the Latest from Summit Partners

Subscribe to our newsletter to stay up to date on our partners, portfolio, and more.

Thank you for subscribing. View the latest issue of The Ascent, or follow Summit Partners on LinkedIn for the latest news and content.
We were not able to submit your form. Please try again.